Biotoxtech Co. Ltd
Biotoxtech Co., Ltd. engages in the safety evaluation of pharmaceuticals, foods, cosmetics, cell therapeutics, chemicals, agrochemicals, and medical equipment in South Korea. It is involved in the PK/TK, ADME, and RI analysis, as well as validation and bio analysis; efficacy evaluation and screening materials; clinical pathology and business contract of histopathology; new drug development; and b… Read more
Biotoxtech Co. Ltd (086040) - Net Assets
Latest net assets as of September 2025: ₩34.06 Billion KRW
Based on the latest financial reports, Biotoxtech Co. Ltd (086040) has net assets worth ₩34.06 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩132.45 Billion) and total liabilities (₩98.39 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩34.06 Billion |
| % of Total Assets | 25.71% |
| Annual Growth Rate | 4.82% |
| 5-Year Change | 19.56% |
| 10-Year Change | 69.95% |
| Growth Volatility | 11.13 |
Biotoxtech Co. Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Biotoxtech Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biotoxtech Co. Ltd (2011–2024)
The table below shows the annual net assets of Biotoxtech Co. Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩40.08 Billion | -16.90% |
| 2023-12-31 | ₩48.23 Billion | +9.04% |
| 2022-12-31 | ₩44.23 Billion | +7.51% |
| 2021-12-31 | ₩41.14 Billion | +22.72% |
| 2020-12-31 | ₩33.53 Billion | +11.04% |
| 2019-12-31 | ₩30.19 Billion | -3.40% |
| 2018-12-31 | ₩31.25 Billion | +17.54% |
| 2017-12-31 | ₩26.59 Billion | +8.35% |
| 2016-12-31 | ₩24.54 Billion | +4.06% |
| 2015-12-31 | ₩23.58 Billion | -11.62% |
| 2014-12-31 | ₩26.68 Billion | +4.23% |
| 2013-12-31 | ₩25.60 Billion | -1.26% |
| 2012-12-31 | ₩25.93 Billion | +19.25% |
| 2011-12-31 | ₩21.74 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biotoxtech Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5856277000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩58.56 Million | 0.15% |
| Common Stock | ₩7.98 Billion | 19.91% |
| Other Components | ₩32.04 Billion | 79.95% |
| Total Equity | ₩40.08 Billion | 100.00% |
Biotoxtech Co. Ltd Competitors by Market Cap
The table below lists competitors of Biotoxtech Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Focus Point Holdings Bhd
KLSE:0157
|
$23.10 Million |
|
MasterBeef Group Ordinary Shares
NASDAQ:MB
|
$23.10 Million |
|
Matrimony.Com Limited
NSE:MATRIMONY
|
$23.11 Million |
|
MSC Co. Ltd
KQ:009780
|
$23.11 Million |
|
Kotra Industries Bhd
KLSE:0002
|
$23.09 Million |
|
Shengli Oil & Gas Pipe Holdings Limited
F:GSG
|
$23.09 Million |
|
CHINA NEW CITY COMM.
F:C7B
|
$23.08 Million |
|
PBG S.A
SA:PTBL3
|
$23.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biotoxtech Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 51,710,249,620 to 40,082,120,000, a change of -11,628,129,620 (-22.5%).
- Net loss of 6,427,237,040 reduced equity.
- Share repurchases of 997,412,460 reduced equity.
- Other factors decreased equity by 4,203,480,120.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-6.43 Billion | -16.04% |
| Share Repurchases | ₩997.41 Million | -2.49% |
| Other Changes | ₩-4.20 Billion | -10.49% |
| Total Change | ₩- | -22.49% |
Book Value vs Market Value Analysis
This analysis compares Biotoxtech Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.24x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.86x to 1.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1705.53 | ₩3165.00 | x |
| 2017-12-31 | ₩1836.93 | ₩3165.00 | x |
| 2018-12-31 | ₩2150.46 | ₩3165.00 | x |
| 2019-12-31 | ₩2074.08 | ₩3165.00 | x |
| 2020-12-31 | ₩2297.16 | ₩3165.00 | x |
| 2021-12-31 | ₩2811.05 | ₩3165.00 | x |
| 2022-12-31 | ₩3022.25 | ₩3165.00 | x |
| 2023-12-31 | ₩3246.60 | ₩3165.00 | x |
| 2024-12-31 | ₩2549.63 | ₩3165.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biotoxtech Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15.55%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 3.40x
- Recent ROE (-16.04%) is below the historical average (0.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 16.39% | 14.18% | 0.52x | 2.21x | ₩1.28 Billion |
| 2012 | 5.55% | 7.63% | 0.40x | 1.83x | ₩-1.09 Billion |
| 2014 | -17.44% | -30.01% | 0.32x | 1.84x | ₩-7.12 Billion |
| 2015 | -17.22% | -23.42% | 0.37x | 2.00x | ₩-6.17 Billion |
| 2016 | 4.26% | 4.69% | 0.46x | 1.96x | ₩-1.41 Billion |
| 2017 | 5.23% | 5.44% | 0.43x | 2.25x | ₩-1.27 Billion |
| 2018 | 11.60% | 13.30% | 0.43x | 2.02x | ₩498.76 Million |
| 2019 | -5.24% | -6.12% | 0.43x | 1.99x | ₩-4.60 Billion |
| 2020 | 7.80% | 9.89% | 0.42x | 1.90x | ₩-738.94 Million |
| 2021 | 17.29% | 21.74% | 0.36x | 2.21x | ₩3.00 Billion |
| 2022 | 6.16% | 7.31% | 0.30x | 2.84x | ₩-1.70 Billion |
| 2023 | -9.43% | -14.95% | 0.22x | 2.84x | ₩-10.05 Billion |
| 2024 | -16.04% | -15.55% | 0.30x | 3.40x | ₩-10.44 Billion |
Industry Comparison
This section compares Biotoxtech Co. Ltd's net assets metrics with peer companies in the Biotechnology & Medical Research industry.
Industry Context
- Industry: Biotechnology & Medical Research
- Average net assets among peers: $62,986,436,140
- Average return on equity (ROE) among peers: -13.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biotoxtech Co. Ltd (086040) | ₩34.06 Billion | 16.39% | 2.89x | $23.09 Million |
| Macrogen Inc (038290) | $118.01 Billion | 2.24% | 0.52x | $99.46 Million |
| Panagene Inc (046210) | $30.94 Billion | 0.00% | 0.90x | $33.82 Million |
| Cell Biotech Co. Ltd (049960) | $52.36 Billion | 19.87% | 0.10x | $43.22 Million |
| Bioneer Corporation (064550) | $26.11 Billion | -55.21% | 1.44x | $176.56 Million |
| MEDIPOST Co. Ltd (078160) | $143.31 Billion | -3.74% | 0.25x | $201.51 Million |
| Peptron Inc (087010) | $7.18 Billion | -42.42% | 0.61x | $4.14 Billion |